GlobeNewsWire
03 Jun 2026, 13:45 UTC · 2h ago
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
Search tags
GlobeNewsWire
03 Jun 2026, 13:45 UTC · 2h ago
Search tags
Story key points
5 claims · impact-rated
The FDA has cleared MAIA Biotechnology to open U.S. enrollment for the expansion of the Phase 2 THIO-101 trial of ateganosine for advanced non-small cell lung cancer (NSCLC). — Expanding trials into the U.S. market is a critical regulatory hurdle and a prerequisite for significant commercialization and FDA approval.
+0.60Additional data from the THIO-101 expansion studies may be used to support a filing for FDA Accelerated Approval. — The potential for an Accelerated Approval pathway significantly shortens the time to market and increases the probability of near-term revenue.
+0.50MAIA is concurrently enrolling patients in a pivotal Phase 3 trial (THIO-104) involving up to 300 third-line NSCLC patients. — The progression to a Phase 3 pivotal trial indicates the drug candidate is moving toward the final stage of clinical validation.
+0.40Continue reading
6 related stories
The FDA previously granted Fast Track designation to ateganosine in July 2025. — Fast Track designation facilitates more frequent communication with the FDA and potential priority review, reducing regulatory risk.
+0.30MAIA has updated its IND to include improved manufacturing protocols, new manufacturers, and revised formulation and storage conditions. — Solving manufacturing and scalability issues is a necessary operational milestone to support commercial launch.
+0.20Ticker attribution
Model heads
Received FDA clearance to open U.S. enrollment for a Phase 2 trial expansion and has a Fast Track designation for its lead candidate.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
10h ago
